CDKN2A and acute myeloid leukemia: The main genetic mutations of HL60 are known (MYC amplified; CDKN2A, NRAS, and TP53 mutated) (Dalton et al., 1988), but owing to significant heterogeneity in the mutation profiles between patients with AML and subtypes, it is still unclear which of the WHO-classified AML subtype HL60 might represent.